白細胞介素-6 (IL-6) 抑制劑的開發平台分析:臨床試驗&結果、專利、指定、聯盟、其他趨勢
Interleukin-6 (IL-6) Inhibitors Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
|出版商||P&S Market Research Pvt. Ltd||商品編碼||600278|
|出版日期||內容資訊||英文 107 Pages
|白細胞介素-6 (IL-6) 抑制劑的開發平台分析:臨床試驗&結果、專利、指定、聯盟、其他趨勢 Interleukin-6 (IL-6) Inhibitors Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments|
|出版日期: 2017年11月01日||內容資訊: 英文 107 Pages||
本報告提供白細胞介素-6 (IL-6) 抑制劑的開發平台趨勢調查，各階段、分子類型、投藥途徑、企業的開發平台趨勢，藥物簡介，競爭環境，主要企業的基準，主要企業簡介等彙整。
IL-6 inhibitors currently exhibits a growing pipeline with approximately 18 active drug candidates, P&S Market Research
IL-6 inhibitors therapeutics pipeline in 2017
The study analyzed that the IL-6 inhibitors therapeutics pipeline comprises approximately 18 active drug candidates in different stages of development. Interleukin-6 inhibitors acts on the IL-6 receptor. IL-6 receptors belong to a group of cytokine receptors that are expressed by leukocytes and plays an important role in the functioning of the immune system. It has a characteristic role in systemic inflammation in numerous disease conditions, including rheumatoid arthritis, and psoriatic arthritis.
Insights on pipeline segments
According to the research findings, most of the drug candidates of the IL-16 inhibitors are being developed as the monoclonal antibody.
Positive Clinical Results of IL-6 Inhibitors Therapeutics Candidates
The positive clinical results from IL-6 inhibitors drug candidates have been driving the pipeline growth. GlaxoSmithKline plc presented results from two pivotal Phase III studies (NCT01606761; NCT02019472) evaluating subcutaneous sirukumab. In both the studies, sirukumab met the primary endpoint showing significant improvement in the signs and symptoms of moderately to severely active rheumatoid arthritis compared to placebo.
Various collaborations for IL-6 Inhibitors therapeutics drug development
In January 2017, Tiziana Life Sciences plc acquired an exclusive world-wide license for NI-1201, a fully human anti-IL-6R monoclonal antibody (mAb), from Novimmune SA. In exchange for the exclusive license from Novimmune SA, Tiziana Life Sciences plc agreed to an upfront cash payment, milestone payments, and a royalty on future sales.
Some of the key players developing drugs for the treatment of IL-6 inhibitors therapeutics include GlaxoSmithKline plc, Chugai Pharmaceutical Co., Ltd., Vitaeris Inc. and others.
IL-6 Inhibitors Therapeutics Pipeline Analysis
By Molecule Type
By Route of Administration
Phase I: Drug profiles